Tetratherix Secures Ethics Approval for 240Patient Pivotal Spacer Trial
Tetratherix has secured Human Research Ethics Committee (HREC) approval in Australia to launch its international pivotal clinical trial for the TutelixTM hydrogel spacer, targeting approximately 240 patients across dual regulatory pathways. The trial is designed to support both TGA and FDA 510(k) submissions, with 50% of patients to be enrolled in Australia and 50% in the United States. Australian enrolment is now expected to commence in Q1 FY27, ahead of the timeline outlined in the company’s prospectus, with US enrolment to follow subject to Investigational Device Exemption (IDE) approval. Ethics approval represents a critical de-risking milestone that advances the company toward regulatory clearances in two major markets.
Tutela pilot study completes enrolment with zero product-related adverse events
The Tutela clinical study has completed enrolment of all 15 patients across multiple Australian sites, with the TutelixTM spacer demonstrating a clean safety profile throughout. Zero product-related adverse events have been recorded at any follow-up time point. The study has consistently confirmed the following clinical observations:
- TutelixTM spacer maintains its structure post-implantation
- No migration from the injection site
- Facilitates simple and safe administration under trans-rectal ultrasound (TRUS)
- Effectively creates and maintains space between the prostate and rectum
- Optimises radiation delivery and reduces rectal radiation dose
A clean safety profile in the pilot study reduces clinical risk heading into the pivotal trial. Full enrolment completion also demonstrates operational execution as the company advances toward larger-scale patient recruitment.
When big ASX news breaks, our subscribers know first
What is a hydrogel spacer and why does it matter in radiation oncology?
Hydrogel spacers address a fundamental challenge in cancer treatment: when tumours sit close to healthy organs, radiation dose must be limited to avoid damaging surrounding tissue, which can compromise treatment effectiveness. An injectable hydrogel spacer temporarily creates physical separation between the tumour site and healthy tissue, allowing higher and more targeted radiation doses whilst protecting adjacent organs from excessive exposure.
Spacer technology has been standard care for prostate cancer patients for over a decade, with multiple regulatory cleared products available. The TutelixTM hydrogel spacer is designed to address this clinical need for prostate cancer patients whilst potentially expanding into new indications where no approved products currently exist.
Six-month follow-up data opens pathway to gynaecological cancer indication
Six-month follow-up data has been collected for one-third of the Tutela study patients, demonstrating that the TutelixTM spacer maintains structural stability and spacing capability for at least six months post-implantation. This sustained performance under anatomical pressure provides a technical basis to pursue a gynaecological cancer indication, where the product would address an unmet clinical need.
Dr Ali Fathi, CTO of Tetratherix
“The positive six-month follow-up data confirms an exciting opportunity beyond the prostate program. TutelixTM maintaining its structure and holding space under sustained anatomical pressure gives us a technical basis to pursue a gynaecological indication where no commercially approved product has existed.”
Platform expansion potential increases the total addressable market without requiring a fundamentally different product. The same spacer technology could serve multiple oncology indications, leveraging the existing clinical and manufacturing infrastructure.
Addressing the unmet need in women’s cancer treatment
No hydrogel spacer has ever been approved for gynaecological cancer treatment anywhere in the world, despite spacer technology being standard care for men with prostate cancer for over a decade with multiple products cleared. The gynaecological site poses a different technical challenge: the weight of abdominal anatomy places greater sustained pressure on a spacer compared to the prostate site, requiring a product that can maintain structural integrity under these conditions.
The Tutela six-month data confirms the TutelixTM spacer could possibly sustain separation under greater anatomical pressures, providing a platform proof point for potential expansion into this neglected oncology segment. The patient impact of this treatment gap is measurable in survival outcomes.
| Metric | Data Point |
|---|---|
| Women receiving radiotherapy with treatment >75 days (initial target markets) | Over 20,000 per year |
| Three-year survival rate (treatment completed within window) | Approximately 88% |
| Three-year survival rate (treatment exceeds 75 days) | Approximately 42% |
Protective spacing created using TutelixTM, by enabling more effective dose delivery within the critical treatment window and reducing toxicity, has the potential to directly influence patient outcomes. No spacer product has been approved for this indication anywhere in the world, representing an unmet clinical need and a currently neglected oncology market.
The next major ASX story will hit our subscribers first
Accelerated pathway and upcoming milestones
The company has outlined near-term catalysts across FY27:
- Australian pivotal trial enrolment to commence Q1 FY27
- US pivotal trial enrolment to follow subject to IDE approval
- Continued follow-up data collection from the Tutela pilot study
- Potential regulatory and development pathway for gynaecological indication to be defined
The timeline has accelerated versus the original prospectus, demonstrating management execution ahead of schedule. Tetratherix is advancing toward dual regulatory submissions (TGA and FDA 510(k)) with a clean safety profile established in the pilot study, whilst simultaneously expanding the potential addressable market through platform extension into gynaecological cancers. This provides clear line of sight to multiple value-creating milestones across FY27, with optionality from the gynaecological indication adding to the investment case.
The zero adverse events result mirrors the safety profile Tetratherix has established across its broader pipeline, including the TetraDerm scar prevention program, which also recorded zero adverse events across its clinical study cohorts while targeting a separate US$2.1 billion wound closure market.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with expert analysis. The Big News Blast delivers market-moving biotech announcements straight to your inbox before the market reacts. Click the Free Alerts button to start receiving real-time alerts the moment clinical trial results and regulatory approvals are announced.